A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR Mutation
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2017
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors Vertex Pharmaceuticals
- 09 Jun 2017 According to a Vertex Pharmaceuticals media release, data were presented the 40th European Cystic Fibrosis Society (ECFS) Conference.
- 26 Oct 2016 Status changed from active, no longer recruiting to completed.
- 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.